The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict CVS Caremark's revenues will increase 16.5% and EPS will improve 23.1%.
The average estimate for revenue is $31.02 billion. On the bottom line, the average EPS estimate is $0.80.
Last quarter, CVS Caremark chalked up revenue of $30.80 billion. GAAP reported sales were 20% higher than the prior-year quarter's $25.70 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.65. GAAP EPS of $0.59 for Q1 were 13% higher than the prior-year quarter's $0.52 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 16.6%, 190 basis points worse than the prior-year quarter. Operating margin was 4.6%, 50 basis points worse than the prior-year quarter. Net margin was 2.5%, 30 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $122.79 billion. The average EPS estimate is $3.33.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 1,660 members out of 1,727 rating the stock outperform, and 67 members rating it underperform. Among 412 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 401 give CVS Caremark a green thumbs-up, and 11 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on CVS Caremark is outperform, with an average price target of $48.68.
If you're interested in retailers like CVS Caremark as investments, you should check out the retail concept that is The Motley Fool's top stock for 2012. Its founder wrote the book on big-box retailing, and it's growing in increasingly important international markets. Click here for instant access to this free report.
- Add CVS Caremark to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Is CVS Health Corporation a Buy in 2018?
There are good reasons to buy the pharmacy giant -- but good reasons to stay away, too.
These 3 Healthcare Stock Dividends Could Soar If Trump Signs a Tax Reform Bill
A corporate tax rate reduction will raise some boats a lot higher than others.
5 Top Stocks for December
Rebalancing your portfolio for the new year? These stocks should be at the top of your buy list.